(NASDAQ: CLDX) Celldex Therapeutics's forecast annual revenue growth rate of -13.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Celldex Therapeutics's revenue in 2024 is $6,072,000.On average, 3 Wall Street analysts forecast CLDX's revenue for 2024 to be $188,899,631, with the lowest CLDX revenue forecast at $13,182,110, and the highest CLDX revenue forecast at $342,734,850. On average, 2 Wall Street analysts forecast CLDX's revenue for 2025 to be $283,415,356, with the lowest CLDX revenue forecast at $210,913,754, and the highest CLDX revenue forecast at $355,916,959.
In 2026, CLDX is forecast to generate $210,913,754 in revenue, with the lowest revenue forecast at $210,913,754 and the highest revenue forecast at $210,913,754.